Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
NGO · Ireland
Industry association · Belgium
Declared costs: €500K+ a year · in the register since 2009
Medicinal products for human use · Compulsory licensing of patents in crisis situations
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Medicines for Europe · filed 22 Apr 2021 · source
Medicines for Europe represents manufacturers of off-patent medicines supplying close to 70% of dispensed prescription medicines in Europe. The pharmaceutical legislation should foster access to follow-on off-patent medicines on day-1 after IP expiry by extending the scope and harmonising the Bolar exemption to cover API supply and all administrative steps needed to effectively launch generic/biosimilar medicines.
Access to Medicines Ireland · filed 26 Apr 2021 · source
Access to Medicines Ireland (AMI) welcomes the opportunity to contribute to the revision of the general pharmaceutical legislation. We have comments, and recommendations in the following areas: Unmet Need 1. Towards a definition of ‘unmet need’, we recommend developing a fair, equitable and transparent decision-making process for what is an ‘unmet need’. 2.
Medicines for Europe · filed 29 Sept 2023 · source
Medicines for Europe, representing manufacturers of generic, biosimilar and value added medicines across Europe, welcomes the proposals to review the EU general pharmaceutical legislation. As the off-patent sector accounting for 70% of medicines dispensed in Europe covering 80% of therapeutic areas, we fully share the goals of ensuring that all patients across the EU have timely and equitable access to safe…
Medicines for Europe · filed 29 Sept 2023 · source
Medicines for Europe, representing manufacturers of generic, biosimilar and value added medicines across Europe, welcomes the proposals to review the EU general pharmaceutical legislation. As the off-patent sector accounting for 70% of medicines dispensed in Europe across 80% of therapeutic areas, we fully share the goals of ensuring that all patients in the EU have timely and equitable access to safe, effective and…
Medicines for Europe · filed 27 Apr 2022 · source
Medicines for Europe welcomes the chance to provide feedback on the proposal to review the compulsory licensing system in Europe. Medicines for Europe is strongly convinced that voluntary licensing agreements are the right way forward to tackle health crises.
Access to Medicines Ireland · filed 29 Apr 2022 · source
Compulsory Licensing in the EU: Call for Evidence Submission by Access to Medicines Ireland (AMI) 29 April 2022 [max 4000 characters] AMI is a voluntary membership group of Cómhlamh, and we welcome the opportunity to provide feedback on the EU’s proposal to review the compulsory licensing in Europe.
Medicines for Europe · filed 28 Jul 2023 · source
Medicines for Europe welcomes the opportunity to provide valuable feedback on the EC proposal to review the compulsory licensing system in Europe. At Medicines for Europe, we firmly maintain that voluntary licensing agreements present the most effective approach to tackle health crises.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.